Eden Research (EDEN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 4.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 11.85
  • 52 Week Low: 3.40
  • Currency: UK Pounds
  • Shares Issued: 533.35m
  • Volume: 255,065
  • Market Cap: £22.67m

Eden Research pens distribution agreement for grape fungicide

By Duncan Ferris

Date: Monday 15 Oct 2018

LONDON (ShareCast) - (Sharecast News) - Eden Research on Monday signed an exclusive distribution agreement for Sipcam to sell grape fungicide product Novellus in Australia and New Zealand.
The biopesticide product supplier said an application for the registration of the product has been submitted to the Australian regulatory authorities and the process is anticipated to be completed in time for the 2020 growing season.

Sean Smith, chief executive of Eden, said: "We are pleased to be taking the first step toward expanding the existing relationship we have with Sipcam, who has already proven to be a good commercial partner for the product in Italy and Spain. We anticipate the further expansion of our relationship with Sipcam in due course as our collaboration continues under the various agreements signed last year."

Novellus, which is used primarily for the treatment of botrytis on grapes, is currently sold in Europe and Africa, with Sipcam already holding exclusive distribution rights in Spain and Italy.

Botrytis fungus affects a variety of plant species, but it is particularly problematic for grape growers due to the rapid progression of the disease and its significant impact on crop yield and wine quality.

"There is a clear opportunity for Novellus to help growers control botrytis in Australia and New Zealand. The fact that Novellus can also be used close to harvest will provide a valuable replacement for iprodione," said Smith.

Iprodione, a rival fungicide, has been removed from sale in Europe and the Australian wine research institute recommends that products containing the substance should not be used on grapes destined for export.

Analysts at Shore Capital, where Eden is a house stock, said: "Today's announcement represents further progress by Eden's management, in our view, in both increasing its distribution of its first commercial product as well as further deepening its relationship with Sipcam."

Eden's shares were up 2.61% at 11.80p at 0945 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Eden Research Market Data

Currency UK Pounds
Share Price 4.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 11.85
52 Week Low 3.40
Volume 255,065
Shares Issued 533.35m
Market Cap £22.67m

Eden Research Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
33.98% below the market average33.98% below the market average33.98% below the market average33.98% below the market average33.98% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income Not Available
Growth
5.67% above the market average5.67% above the market average5.67% above the market average5.67% above the market average5.67% above the market average
5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average

Eden Research Dividends

No dividends found

Trades for 26-Apr-2024

Time Volume / Share Price
15:25 10,000 @ 4.33p
13:14 8,000 @ 4.33p
12:31 15,000 @ 4.34p
12:18 7,533 @ 4.34p
12:18 7,936 @ 4.17p

Eden Research Key Personnel

CFO Alexander John Abrey
CEO Sean M. Smith

Top of Page